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ABSTRACT
A number of candidate histopathologic factors show promise in identifying 
stage II colorectal cancer (CRC) patients at a high risk of disease-specific death, 
however they can suffer from low reproducibility and none have replaced classical 
pathologic staging. We developed an image analysis algorithm which standardized 
the quantification of specific histopathologic features and exported a multi-parametric 
feature-set captured without bias. The image analysis algorithm was executed across 
a training set (n = 50) and the resultant big data was distilled through decision tree 
modelling to identify the most informative parameters to sub-categorize stage II 
CRC patients. The most significant, and novel, parameter identified was the ‘sum 
area of poorly differentiated clusters’ (AreaPDC). This feature was validated across 
a second cohort of stage II CRC patients (n = 134) (HR = 4; 95% CI, 1.5– 11). 
Finally, the AreaPDC was integrated with the significant features within the clinical 
pathology report, pT stage and differentiation, into a novel prognostic index (HR = 7.5; 
95% CI, 3–18.5) which improved upon current clinical staging (HR = 4.26; 95% 
CI, 1.7– 10.3). The identification of poorly differentiated clusters as being highly 
significant in disease progression presents evidence to suggest that these features 
could be the source of novel targets to decrease the risk of disease specific death.
INTRODUCTION
Recent reports have demonstrated the potential 
value of automated image analysis and claimed it as 
an alternative to conventional clinical histopathologic 
analysis. The methodology allows the identification and 
quantification of novel features or the capture of spatial 
heterogeneity across a tissue section; however neither 
of which are currently part of routine histopathologic 
assessment [1, 2]. We have previously shown that 
automated image analysis complements, rather than 
replaces, routine histopathology by standardizing the 
quantification of prognostic histopathologic features in 
CRC [3]. Unless automated analysis significantly adds to 
standard practice there will remain a significant barrier to 
clinical implementation. Here we demonstrate a workflow 
which utilizes image analysis to extract standardized big 
data from histopathologic tissue sections and machine 
learning to distill the most significant resultant parameters 
addressing a specific clinical question. Furthermore we 
show how the image analysis based quantification of 
a tissue sample can be integrated into existing clinical 
parameters where the aim is to augment rather than replace 
gold standard practice. The study demonstrates the value of 
the approach using colorectal cancer as a worked example.
Patients with colorectal cancer (CRC) are staged 
by the Tumor, Node and Metastasis (TNM) system, 
although genetic analyses are increasingly a routine part 
of diagnosis and sub-classification [4–6]. TNM staging 
is good for prediction of disease progression across the 
patient population,  however it is much less successful at 
predicting the outcome for individual patients [7]. This is 
exemplified by the fact that although surgical resection is 
hoped to be curative for stage II patients,  20% of these 
patients go on to experience disease-specific death [8]. It 
is imperative to identify these high risk stage II patients 
for the inclusion in future clinical trials or to ascertain if 
detailed follow up could be beneficial [9]. 
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There have been multiple attempts to improve 
on patient prognosis and to identify novel clinical 
targets through molecular biomarker analysis and novel 
histopathologic grading systems, where the invasive 
margin of CRC is of particular significance [10–12]. 
Although these features may have prognostic value 
they have not been adopted into routine clinical practice 
for several reasons, including observer variability 
and non-standardized quantification [13–15]; both 
of which might be overcome using automated image 
analysis. Furthermore, there could exist unrecognized 
morphological features containing targetable or prognostic 
information within the complex and heterogeneous CRC 
microenvironment. We therefore built an image analysis 
algorithm which standardized the quantification of a range 
of candidate prognostic features from the invasive margin 
of CRC and which have previously shown prognostic 
significance: tumor budding (TB) [16, 17], poorly 
differentiated clusters (PDC) [11, 18], lymphatic vessel 
invasion (LVI) [19], lymphatic vessel density (LVD)
[20, 21] and the tumor to stroma ratio [22, 23]. These 
known features were furthermore compared to other 
morphometric and spatial parameters captured without 
bias and measured using hierarchical image analysis. 
RESULTS
Image analysis and processing workflow
We have developed a novel image analysis 
algorithm which quantified candidate histopathologic 
features in an objective and standardized manner while 
simultaneously capturing a large, extracted set of unbiased 
features (123 features in total). The most informative 
features were subsequently distilled through decision tree 
modelling. The image processing workflow (Figure 1) 
was designed to identify the most significant conventional 
or novel feature-set capable of classifying high or low 
risk of disease specific death in stage II CRC patients. 
The workflow was carried out across a training set of 
50 patients and the significant parameters identified were 
validated across a cohort of 134 patients.
Image segmentation and data export
The algorithm automatically segmented the 
immunofluorescence labelled digital tissue sections in 
a hierarchical format (Figure 2A). Immunofluorescence 
allowed the accurate digital segmentation of stroma, 
tumor glands (pan cytokeratin (panCK)), invasive 
tumor subpopulations (panCK), lymphatic vasculature 
(D2- 40) and all nuclei (DAPI). These objects were sub-
classified into candidate histopathologic features prior to 
quantification: tumor buds, poorly differentiated clusters, 
lymphatic vessel invasion, minimal lymphatic vessel 
invasion (less than 5 tumor cells invading vessel), lymphatic 
vessel density and tumor to stroma ratio. These parameters 
were specifically included in the algorithm for standardized 
quantification as they have been shown to have prognostic 
value but are difficult to accurately reproduce. Furthermore 
morphometric, density, spatial and fluorescence intensity 
and texture measurements were captured and exported from 
the hierarchically segmented objects in an unbiased manner 
(Figure 2B and 2C). In such a fashion, parameters were 
extracted from objects across each level of image analysis 
(Figure 2A). The hierarchical and spatial re-classifying 
of objects was integrated into the algorithm to capture 
an aspect of the complex tumor heterogeneity that exists 
across the invasive front of the CRC microenvironment. 
The full 123 parameter data-set for each patient sample 
was subsequently exported and collated (Supplementary 
Table 1). An extended description of algorithm results and 
associated Figures is listed in Supplementary Document 1.
Visualization of the multi-parametric feature-set
The complex and high dimensional multi-parametric 
feature-set was visualized in a 2D scatter plot after principal 
component analysis (PCA) was performed (Figure 3). The 
2 plotted principal components explained 72% variance 
in the full 50 patient training set data. Performing PCA 
allowed the evaluation of the effectiveness of the full multi-
parametric feature-set to categorize patients within the full 
training cohort into high or low risk of disease specific 
death. In the stage II subpopulation of the training set there 
was only one outlier patient who survived follow up and 
which clustered within the poor outcome group (Figure 3B). 
The clustering of the full multi-parametric feature-set across 
the 50 patient training cohort allowed patient categorization 
on disease specific death with 100% specificity, 78.6% 
sensitivity and an area under the ROC curve of 0.89. 
When analyzing the 29 stage II patient subpopulation of 
the training set, the results were 100% specificity, 93.3% 
sensitivity and an area under the ROC of 0.94.  
Parameter reduction
Although clustering of the multi-parametric 
data resulted in the significant categorization of CRC 
patients on disease specific death, PCA did not report 
which of the parameters held prognostic significance. To 
eliminate redundant parameters, while retaining a robust 
stratification model, we performed random forest analysis. 
The 123 parameters within the full multi-parametric 
feature-set and the full 50 patient training set data were 
the input for random forest analysis. After analysis the 
123 parameters were ranked by their associated Gini 
score and the least significant parameter was removed. 
This process was performed iteratively until the removal 
of a parameter affected the predictive value of the model 
in a negative manner. The method resulted in a set of 37 
parameters (Supplementary Table 1) which had the ability 
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to categorize patients on risk of CRC specific death with 
the same predictive value as the full multi-parametric 
feature-set (100% specificity, 76.7% sensitivity, area under 
the ROC curve of 0.89).
Novel histopathologic feature identification
Random forest removed 86 redundant parameters 
from the full multi-parametric feature-set. The remaining 
37 significant parameters were used as input to construct 
a Classification and Regression Tree (CART) model. 
The CART model exported a single decision tree where 
parameter relationships and optimal cut-offs for each 
branch-point within the tree can be reported. CART 
therefore allows clinically transferable tests to be created 
from the calculated cut-offs within the optimal parameters 
reported.
In this study a single parameter was exported within 
the decision tree as the optimal model. This parameter 
was the “sum area of poorly differentiated clusters” 
(AreaPDC) across the invasive front of each tissue section. 
The inclusion of any further image-based parameters did 
not, therefore, add to the significance of the model. This 
single parameter had the ability to significantly categorize 
the 50 patients from the training cohort by disease specific 
death with a specificity of 96.3%, a sensitivity of 82.6% 
and an area under the receiver operator curve (ROC) of 0.9. 
When the 29 stage II subpopulation of the training cohort 
was analyzed separately the results were more significant 
and returned a specificity of 100%, a sensitivity of 93.75% 
with an area under the ROC of 0.96. The CART model 
performed 10 fold self-test validation on the full 50 patient 
training cohort data setwhich reported a specificity of 83.3% 
and sensitivity of 75% and an area under the ROC of 0.8.
The CART model provided the optimal cut-off 
from the continuous data captured from the full 50 patient 
training set across the novel parameter AreaPDC. This 
cut-off, 35,647 µm2, was applied to categorize the patients 
into groups of high and low risk of disease specific death. 
Kaplan-Meier curves were subsequently plotted and 
reported that the AreaPDC was a significant predictor of 
poor survival and shorter disease specific survival times 
in both the full 50 patient training cohort (p < 0.0001) 
and its 29 patient stage II subpopulation (p < 0.0001) 
(Supplementary Figure 6). Univariate cox-regression 
reports that the parameter AreaPDC is a highly significant 
predictor of disease specific death in the training cohort 
(HR = 20; 95% CI, 4.6–87.9).
Figure 1: Image processing workflow. Steps involved in the imaging process workflow described in this study; from initial image 
analysis through to the identification of significant parameters by decision tree modelling. This workflow is amenable to any multi-
parametric data set where significant parameters and their clinically applicable cut-offs need to be identified.
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Validation of image based prognostic features
The analysis algorithm was executed across tissue 
sections cut from the 134 stage II patient validation 
set. This was performed primarily to validate the novel 
prognostic parameter of AreaPDC which we identified in 
this study. Secondly to compare the prognostic significance 
of the image analysis quantified set of candidate 
histopathologic features and the novel parameter.
The validation set patients were separated into 
categorical groups of either above or below the training set 
cut-offs for each parameter. Optimal validated cut-offs and 
their prognostic significance for the training set are listed 
in Supplementary Table 2. Disease specific death statistics 
were calculated as univariate Cox-regression and Kaplan-
Meier analysis for the validation set data. Univariate Cox-
regression reported that tumor budding (HR = 2.5; 95% 
CI, 1–6), minimal lymphatic vessel invasion (HR = 2.5; 
Figure 2: Automated data extraction from analyzed images. (A) Image based parameters are extracted from each of the 
hierarchical layers of the image analysis algorithm.  The top layer (ROI level) segments tumor from lumen/necrosis and from stroma. The 
‘object level’ contains segmented objects such as a lymphatic vessel (LV) or tumor bud (TB) which exist exclusively within an ROI in 
the layer above e.g. the stroma. The final layer of the hierarchy is the ‘nucleus level’ and contains all segmented nuclei. Nuclei are further 
segregated into either an object (e.g. tumor) in the ROI level or object (e.g tumor bud) in the object level. The hierarchical approach 
allows for the capture of heterogeneity across the invasive microenvironment. (B) Extraction of parameter classes across nuclei segregated 
within three distinct heterogeneous objects/ROIs: Tumor gland (nucleus highlighted by green arrow), stroma (nucleus highlighted by red 
arrow) and tumor bud (nucleus highlighted by blue arrow). (C) Visualization of the extraction of different parameter classes and example 
parameters across the heterogeneous objects (e.g. tumor gland; purple, poorly differentiated cluster (PDC); blue) within a digital tissue 
image (panCK; green, DAPI; blue).
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95% CI, 1–6), poorly differentiated clusters (HR = 3; 
95% CI, 1.2–9), tumor to stroma ratio (HR = 0.1; 95% 
CI, 0.03–0.6) and the AreaPDC (HR = 4; 95% CI, 1.5– 11) 
were significant predictors of disease specific death 
within the validation set whereas lymphatic vessel density 
and lymphatic vessel invasion were not (Table 1). The 
novel parameter AreaPDC returned a higher associated 
significance (p = 0.007) than any of the candidate 
histopathologic parameters apart from the tumor to stroma 
ratio which reported the same significance (p = 0.007). No 
single parameter identified through image analysis had a 
higher prognostic significance than the clinically reported 
pT stage (HR = 4.26; 95% CI, 1.76–10.33, p = 0.001).
Kaplan-Meier curves were plotted for the significant 
parameters utilizing the categorized validation cohort data 
to assess disease specific survival over time (Figure 4). 
Patients in the high cut-off group for tumor budding (p = 
0.05), poorly differentiated clusters (p = 0.02), minimal 
lymphatic vessel invasion (p = 0.05), AreaPDC (p = 0.003) 
as well as patients in the lower cut-off group for the tumor 
to stroma ratio (p = 0.004)  had a higher risk of disease 
specific death and significantly shorter survival times 
than patients in the alternative group. The Kaplan-Meier 
analysis confirmed the novel parameter of AreaPDC to 
hold the highest significance of the risk of disease specific 
death over time than any of the other histopathologic 
parameters, although this was less than clinical pT staging 
(p = 0.0009).
Novel prognostic index augments clinical staging
The significant parameters reported by univariate 
cox-regression (Table 1), from either image analysis or the 
clinical pathology report, were entered into a multivariate 
backward elimination Cox-regression model. This was 
performed to identify which parameters added significant 
value to an integrative model in its ability to predict CRC 
specific death within the validation set. The integration of 
AreaPDC (p = 0.02), T stage (p = 0.03) and differentiation 
(p = 0.04) increased the significance of a final predictive 
model. The image analysis parameters of tumor budding 
(p = 0.8), poorly differentiated clusters (p = 0.51), minimal 
lymphatic vessel invasion (p = 0.8) and the tumor to 
stroma ratio (p = 0.55) or the clinical parameter of extra-
mural lymphovascular invasion (EM LVI) (p = 0.18) 
did not add further significance to the model and were 
therefore excluded (Table 2A).
The three significant parameters within the forward 
conditional model were compiled into a novel prognostic 
index. Patients with an above cut-off score in two or 
more of the three significant parameters were classified 
as a “high-risk” of disease specific death group and the 
remainder of the patients were classified with a “low-risk” 
score. The novel prognostic index was the sole significant 
parameter to predict disease specific death (HR = 7.5; 95% 
CI, 3–18.5, p = 0.00001) (Table 1) when entered into a 
backward elimination Cox regression model along with its 
Figure 3: Visualization and clustering of the multi-parametric feature set through principal component analysis 
(PCA). The data is plotted in a scatter plot for (A) the full training set and (B) for its stage II subpopulation. Patients who died specifically 
of CRC are plotted as triangles and patients who survived follow up are plotted as circles. The PCA resulted in the significant categorization 
of patients at a high and low risk of disease specific death. DSD = disease specific death.
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Table 1: Validation set patient data
Clinicopathologic parameters patient number (n)
Univariate
HR 95% CI P value
Lower Upper
Clinical pathology report
Stage
  II 134
Gender
  M
  F
69
65
0.93 0.6 1.45 0.76
Age at Diagnosis
  ≤ 70
  71–79
  ≥ 80
52
39
43
1.4 0.82 2.41 0.22
pT Stage
  pT3
  pT4
102
32
4.26 1.76 10.33 0.001
Differentiation
  Well
  Moderate
  Poor
3
109
22
2.17 1.14 4.13 0.018
Histology
  AC
  MC
  AC/MC
121
7
6
0.82 0.27 2.49 0.72
Site
  Rectal
  Right side
  Left side
42
47
45
0.87 0.5 1.51 0.61
Tumor Diameter*
  High
  Low
44
90
1.7 0.66 4.42 0.27
Total Node Examined
  < 12
  ≥ 12
35
99
0.6 0.24 1.5 0.27
EM LVI
  Yes
  No
20
114
2.8 1.1 7.3 0.04
Image Analysis
Tumor Budding
  High
  Low
44
90
2.49 1.03 5.99 0.04
Minimal LVI
  High
  Low
35
99
2.46 1 6.05 0.05
LVI
  High
  Low
27
107
1.9 0.75 5.15 0.16
Tumor to stroma ratio
  High
  Low
76
58
0.13 0.03 0.57 0.007
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composite parts (Table 2B). The novel prognostic index’s 
prediction of CRC specific death reported a significant 
improvement on classical pT staging (HR = 4.26; 95% CI, 
1.76–10.33, p = 0.001) within this stage II CRC patient 
validation cohort.
Kaplan-Meier curves were plotted to assess the 
significance of the novel prognostic index in patient 
survival over time (Figure 5). The novel prognostic index 
significantly categorized stage II CRC patients with a high 
risk of CRC specific death over an 11.5 year follow up 
(p < 0.0001).
DISCUSSION
We have demonstrated that a novel feature, area 
of poorly differentiated clusters (AreaPDC) identified 
through image analysis can augment traditional 
histopathologic staging of stage II CRC, moving toward 
a more personalized prognosis. Furthermore the evidence 
that the involvement of poorly differentiated clusters is 
highly significant in disease progression directs future 
research into the elucidation of their molecular phenotype 
and thereby identifying novel targets to inhibit their 
invasive characteristics. The novel feature (AreaPDC) 
was distilled through decision tree modelling from a 
large hierarchical and multi-parametric feature-set which 
contained both candidate histopathologic features and ones 
captured in an unbiased manner. The data was entered into 
the model with no knowledge a priori of which image 
based parameter would hold clinical significance. The 
multi-parametric feature-set itself was captured through 
a novel image analysis algorithm developed within this 
study and which was executed across digitized CRC 
tissue sections from a training and validation cohort. The 
patients within the validation cohort were significantly 
categorized into high and low risk of disease specific 
death (HR = 4; 95% CI, 1.5–11), depending on their sum 
area of poorly differentiated clusters (AreaPDC) being 
above or below the cut-off of 35647 µm2. AreaPDC was 
more informative than previously reported prognostic 
features which were simultaneously captured across 
each patient sample through the bespoke image analysis 
algorithm, including number of tumor budding [16, 17] 
number of poorly differentiated clusters [11, 18], tumor 
to stroma ratio [22, 23] and lymphatic vessel invasion 
[19]. Although these previous studies reported prognostic 
significance in CRC as individual parameters, none have 
simultaneously co-registered all of the quantified features 
across a single tissue section. We have demonstrated 
here that tumor budding, poorly differentiated clusters, 
tumor to stroma ratio and lymphatic vessel invasion 
also hold univariate significance in the prediction of 
disease specific death but that they become redundant 
and add no further independent value when integrated 
into a multi-variable model which includes the AreaPDC. 
Furthermore predictive significance increased upon the 
creation of a novel prognostic index where AreaPDC was 
integrated with the significant clinical data parameters of 
differentiation and pT stage (HR = 7.5; 95% CI, 3–18.5, 
p = 0.00001). Although the use of continuous data is 
optimal within regression models [24], translatable tests, 
at least for the foreseeable future, rely on a validated cut-
point to inform on clinical decision making. The novel 
feature AreaPDC was therefore dichotomized using the 
validated CART reported cut-off prior to entering into 
regression models which included pre-existing categorical 
clinical data (pT stage and differentiation). Therefore the 
potentially translatable novel prognostic index predicts 
disease specific death in a stage II CRC validation cohort 
with more accuracy than the standalone conventional pT 
staging, however further validation of this index will be 
required.
LVD
  High 
  Low
25
109
1.39 0.46 4.16 0.56
Number PDC
  High 
  Low
18
116
3.03 1.08 8.5 0.04
Area PDC
  High
  Low
65
69
4.02 1.46 11.1 0.007
NPI
  High
  Low
22
112
7.5 3 18.5 0.00001
Patient data was extracted from the clinical pathology report and categorized prior to univariate Cox-regression (top half of 
table). Image analysis data was categorized into above or below training set cut-off (bottom half of table) prior to univariate 
Cox-regression. Novel Prognostic Index (NPI) of integrated Area PDC, pT stage and differentiation is bordered by double 
line. HR = hazard ratio, CI = confidence interval. EM LVI = Extramural lymphovascular invasion, LVI = lymphatic vessel 
invasion, LVD = lymphatic vessel density, PDC = poorly differentiated clusters.  *No entry in pathology report for tumor 
diameter in 18 cases. Parameters in bold were significant; significance was set at (p ≤ 0.05).
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Figure 4: Kaplan-Meier survival curves for the significant histopathologic parameters captured across the validation 
set. Patients within group 1 were below the training set cut-off for the associated parameter and patients within group 2 were above cut-off. 
(A) Tumor budding: training set cut-off of 287 buds. (B) Minimal LVI: training set cut-off of 16 events. (C) Poorly differentiated clusters: 
training set cut-off of 35 clusters. (D) Tumor to stroma ratio: training set cut-off of 21% tumor area of the total tissue. (E) Sum area poorly 
differentiated clusters (AreaPDC): training set cut-off of 35647 µm2. (F) pT stage: pT3 = group1 and pT4 = group 2. (G) Differentiation: 
Well = group 1, Moderate = group 2 and Poor = group 3. FDR = false discovery rate corrected p values.
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Previous studies have demonstrated the advantages 
of image analysis reported large data sets captured in an 
unbiased manner [1] or to quantify set histopathologic 
features [3, 25]. Uniquely, the image analysis algorithm 
developed in this study captured a combination of both 
in a standardized and objective manner and demonstrated 
the validity in principle of such methodology. The 
quantified data was captured in a continuous format which 
allowed optimal cut-offs for parameters to be calculated 
and subsequently validated. The multi-parametric 
feature-set was analyzed in two separate decision tree 
models. Random forest was utilized to negate redundant 
parameters which added no value to the predictive binary 
outcome of disease specific death. A Random forest model 
[26], consisting of 5000 trees, ranked and reduced the 
parameters according to their Gini score and significance 
in the model and is an ideal model for handling large data 
sets. It is not applicable to a clinical prognostic index 
as it does not inform on cut-offs or the combinations 
of parameters which yield the optimal output to stratify 
patients. A CART model [27], which produces a single 
decision tree and works more accurately on smaller 
data sets, was subsequently run across the significant 
parameters identified through random forest. CART 
provides optimal and validated cut-offs for each parameter 
at each branch point within a model and is therefore 
amenable to the identification of a clinically transferable 
histopathologic marker or a combination of markers.
The semi-quantification of current and emerging 
histopathologic features in CRC may suffer from poor 
reproducibility and inter- and intra-observer variability 
[10, 14, 15]. Previous studies in tumor budding and poorly 
differentiated clusters have concentrated on their number 
[16–18, 28] and not their area; which would prove difficult 
to accurately report by eye. Image analysis offers the 
standardization and the fully reproducible quantification of 
Table 2B: Parameters entered into the backwards elimination Cox Regression model
Variables in the equation
Multivariate Cox Regression Model (Ordinal Variables)
HR 95% CI P value
Lower Upper
NPI 7.5 3 18.4 0.00001
Variables not in the equation
Area PDC NS
pT stage NS
Differentiation NS
Variables which add significance (top half of table) and variables which do not add significance (bottom half of table) to an 
integrative model to predict disease specific death. NS = Non-significant. Area PDC = area of poorly differentiated clusters.
Table 2A: Parameters entered into the backwards elimination Cox Regression model
Variables in the equation
Multivariate Cox Regression Model (Ordinal Variables)
HR 95% CI P value
Lower Upper
Area PDC 3.3 1.1 9.3 0.005
pT stage 2.9 1.1 7.3 0.030
Differentiation 2.2 1 4.9 0.046
Variables not in the equation
EMLVI NS
Tumor to stroma ratio NS
TB NS
PDC NS
Minimal LVI NS
Variables which add significance (top half of table) and variables which do not add significance (bottom half of table) to an 
integrative model to predict disease specific death. NS = Non-significant. Area PDC = area of poorly differentiated clusters, 
EMLVI = extramural lymphovascular invasion, TB = tumor budding, PDC = poorly differentiated clusters, Minimal LVI = 
minimal lymphatic vessel invasion.
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features, such as the accurate reporting of the area of poorly 
differentiated clusters (AreaPDC). This study employed 
immunofluorescence for the multiplexing, co-registering 
and accurate quantification of the features captured across 
the CRC tissue section. Lymphatic vessel invasion and 
mesenchymal transitioned invading cancer cells may 
prove particularly obscure under classical H&E stained 
tissue. We acknowledge that although advantageous 
for initial investigative purposes, immunofluorescence 
may not be applicable to routine clinical use. However, 
the single novel parameter AreaPDC can be quantified 
through chromogenic immunohistochemistry using a 
wide spectrum cytokeratin antibody and a much simplified 
image analysis algorithm making it amenable to most 
clinical laboratories. This translational impact would 
still rely on the wider adoption of digital pathology in 
routine clinical practice but which is predicted in the near 
future [29]. Although there are molecular tests to predict 
poor outcome in stage II CRC patients [30] they tend to 
homogenize tissue which destroys spatial heterogeneity. 
Image analysis may unlock a wealth of valuable 
histopathologic information form the heterogeneous tumor 
microenvironment, while retaining the spatial resolution 
of interacting host and tumor subpopulations. In time 
this can be integrated with molecular genetic data [31]. 
The area of poorly differentiated clusters, identified as a 
distinct subpopulation, were the most significant predictor 
of disease specific death and exemplifies heterogeneous 
data which may be lost through molecular testing.
Image analysis across tissue microarrays (TMAs) 
yielded novel prognostic features in breast cancer 
although the authors acknowledged that analyzing whole 
slide images could report a more significant model [1]. 
We found that quantifying the candidate histopathologic 
features across a single core of a TMA per patient yielded 
insignificant results (data not shown). We therefore 
adopted a whole slide imaging approach which allowed 
the identification of the invasive front of the tumor section 
and the capture of high resolution images from within 
this region. We concentrated our analysis on the invasive 
front as the candidate histopathologic features of interest 
are predominantly located in, and conventionally reported 
from, this region. The data captured across these images 
allowed the significant categorization of high risk of 
disease specific death CRC patients. Further investigation 
would need to be performed to identify the optimal 
number of images required to be captured across the 
whole section in order to yield reproducible results across 
potential further validation cohorts.
We utilized proprietary software for the image 
analysis and data mining aspects of this study. We 
endeavored to ensure that the overall workflow presented 
here for novel feature identification from multi-parametric 
data is possible within open source software thus making 
it amenable to most clinical research labs. Both random 
forest and CART can be executed within the statistical 
package R (http://www.statmethods.net/advstats/cart.
html) while image analysis based multi-parametric feature 
extraction can be performed in Image J (http://imagej.nih.
gov/ij/) or Cell Profiler (http://www.cellprofiler.org/). 
Similarly the workflow is not limited to the specific 
immunofluorescence assay, candidate histopathologic 
Figure 5: Kaplan-Meier survival curve for the Novel Prognostic Index. Novel Prognostic Index; patients within group 2 were 
within above cut-off in two or more of the composite parameters while those in group 1 were within above cut-off of one or no composite 
parameters. FDR = false discovery rate corrected p values.
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features or multi-parametric feature set utilized within 
this study but can be applied across any digital pathology 
specimen.
TNM staging aided by the core clinical data-
set [8, 32] has long remained the gold-standard for the 
prediction of CRC disease progression. Although, there 
exists debate on how TNM staging can be improved 
upon while retaining it as central to CRC prognosis 
[33]. Therefore it would seem pertinent to include the 
pathological reporting which already exists into novel 
integrative models. The novel prognostic index reported 
here returned a higher significance of high-risk patient 
identification than the sum of its parts. This study therefore 
demonstrates the value of systematic reporting incorporated 
into a novel prognostic index over the reporting of a single 
feature in isolation. Although image analysis will unlikely 
completely replace conventional histopathology it can 
be applied to standardize the quantification of certain 
histopathologic features and play a vital role in identifying 
novel prognostic and targetable parameters, such as poorly 
differentiated clusters, amenable to clinical translation and 
integration in order to address urgent clinical needs.
MATERIALS AND METHODS
Patient samples
Tissue samples were residual diagnostic tissue 
stored within the NHS Lothian Department of Pathology 
archive. The research was undertaken under the approval 
of the NHS Lothian NRS BioResource and ethical 
approval for the study (13/ES/0126) was granted by the 
East of Scotland Research Ethics Service.
Training set (n = 50): Twenty nine stage II patient 
samples were selected on colorectal specific death (15 
survived follow up: good outcome and 14 died of disease: 
poor outcome) from a Scottish prospectively collected 
CRC cohort. Patient follow up was for at least 15 years. 
Thirteen stage I (12 with good outcome and 1 with poor 
outcome) and 8 stage III (all of whom died of disease) 
patients were randomly selected from the cohort for 
comparison. Patient samples were collected, after surgical 
resection, between the years of 1996 and 2003, from 
hospitals across Scotland. No patients within the training 
cohort underwent neoadjuvant or adjuvant therapy. Patient 
data is listed in Supplementary Table 2. 
Validation set (n = 134): A separate validation set 
comprised all cases of stage II CRC treated in Edinburgh 
(Scotland) hospitals over 2 concurrent years (years 2002 
and 2003),  resulting in a cohort of 147 patients. Clinical 
follow up was up to 11.5 years. Due to insufficient 
available material 13 patients were excluded leaving a 
remaining 134 patients within the validation set; 20 of 
whom died of disease during the follow up period. Of the 
134 patients tested within the validation set 9 rectal cancer 
patients underwent adjuvant therapy and 3 colon cancer 
patients under went adjuvant chemotherapy. Patient data 
is listed in Table 1.
Immunofluorescence and image capture
Samples were prepared for multiplexed 
immunofluorescence with DAPI (nuclei) and antibodies 
against pan-cytokeratin (epithelial cells) and D2-40 
(lymphatic endothelium), as previously outlined [3]. 
Briefly, a 4 µm section was cut from a FFPE tissue 
block, deparaffinised and rehydrated. Microwave based 
antigen retrieval (Tris-EDTA, pH9 buffer), endogenous 
peroxidase (3% H202) and protein block (Dako, X0909) 
steps were undertaken prior to immunofluorescence. 
Immunofluorescence was performed using antibodies 
against wide specificity cytokeratin (pan-cytokeratin) 
(primary antibody: Dako, Z0622, 1:150; Alexa Fluor 
555 secondary antibody: Thermo Fisher Scientific, 
A21428, 1:25) and lymphatic endothelium (D2-40, 
primary antibody: Dako, M3619, 1:2000; HRP labelled 
secondary antibody: Dako, K4001 and Cy5 Tyramide, 
Perkin Elmer, SAT705A001EA, 1:100). Tissue sections 
were counterstained in DAPI Prolong Anti-fade mountant 
(Thermo Fisher Scientific, P36931).
All images were captured on the HistoRx PM-
2000 imaging platform (HistoRx Ltd., Branford, CT, 
USA). Whole slide images were captured with a 4x 
objective through the pan-cytokeratin (Alexa Fluor 555/
Cy3) channel. For each tissue section, the invasive front 
was identified manually from the whole slide image and 
15 high-resolution images were captured, in an evenly 
spaced distribution across the invasive front, through a 
20x objective, with the following settings: DAPI (200 ms 
exposure), Cy3 (35 ms exposure) and Cy5 (200 ms 
exposure), thus visualizing nuclei, pan-cytokeratin 
(panCK) and lymphatics with D2-40 labelling respectively. 
All patient samples were treated in a standardized manner 
as described above. Images are exported from the 
PM- 2000 platform as .TIFF files at highest resolution. 
Each field of view is exported as three separate greyscale.
TIFF files; one for each associated wavelength.
Image analysis
The novel image analysis algorithm was created 
within the Definiens image analysis software packages: 
Tissue Studio® and Developer XD™ (Definiens AG, 
Munich). Images were imported into Definiens as .TIFF 
files. Initial image segmentation utilized an image 
analysis algorithm created in Tissue Studio® as described 
previously [3]. All segmented objects were further 
classified within a hierarchical system where the top level 
was automatically segmented through machine-based 
learning using Definiens Composer Technology™ into 
Regions of Interest (ROIs): ‘tumor’, ‘necrosis/lumen’, ‘no 
tissue’ and ‘stroma’. Next, the object level of the image 
analysis hierarchy captured all panCK and D2-40 positive 
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objects in the stroma. The final layer of image analysis 
identified nuclei through the DAPI channel. Each nucleus 
was exclusively segregated into relevant subpopulations 
existing in the analysis layers above. The Tissue Studio® 
analyzed workspace was subsequently imported into 
Developer XD™ for bespoke object classification, 
optimization and parameter export. A full description of 
the image analysis methods, with accompanying figures 
and settings for the Definiens’ rulesets are listed in 
Supplementary Document 2.
Multi-parametric data extraction
The algorithm quantified the total number of 
objects within each classification as well as extracting 
morphometric, spatial relationships, texture and 
fluorescence measurements from the objects across the 
segmented hierarchical image layers. The parameters 
captured from each of the 15 images taken per tissue 
section were either averaged or summed (depending on 
the nature of the parameter) to equate to one data-point per 
parameter per patient. In total 123 image-based parameters 
were extracted per tissue section and these made up the 
multi-parametric feature-set for each patient sample. A 
table containing the full list of the extracted parameters, 
and their collation method per patient sample, is located 
in Supplementary Table 1.
Statistical analysis
Optimal training set cut-offs 
The unprocessed, continuous data for each 
candidate histopathologic feature (tumor budding, 
poorly differentiated clusters, lymphatic vessel invasion, 
minimal lymphatic vessel invasion, tumor to stroma ratio 
and lymphatic vessel density) alongside patient outcome 
data was loaded into X-Tile software [34] to calculate the 
optimal cut-offs to categorize patients into high or low 
risk of disease-specific death. The significance of these 
cut-offs were corrected by cross-validation within Monte-
Carlo simulations (n = 1000). Training set cut-offs were 
subsequently applied to the validation set to categorize the 
stage II patient population.
Modelling to identify significant parameters
Principle Component Analysis and Cox regression 
calculations (univariate and multivariate backwards 
elimination with a stopping rule based on Aikaike´s 
Information Criteria) were performed in SPSS (IBM, 
New York, USA). From the 123 multi-parametric feature 
set the most informative features which differentiated 
between binary disease specific survival were identified 
by inputting the continuous data for each parameter into 
a random forest (n = 5000) decision tree model [26] and 
exporting the associated Gini score. The continuous data 
from each informative parameter was subsequently input 
into a classification and regression tree (CART) [27] 
decision tree strategy to identify optimal combinations of 
and clinical cut-offs of novel significant histopathologic 
features (Salford Predictive Miner, Salford Systems, San 
Diego, USA). To avoid over-fitting within the decision 
tree modelling, validation was performed during the 
decision tree modelling for both random forest (out of 
bag) and CART (10 fold self-test). Kaplan Meier curves 
and associated Benjamini-Hochberg false discovery rate 
corrected p values were calculated using TMA Navigator 
(http://www.tmanavigator.org) [35]. 
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